In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia

Blood

Volumn 99, Issue 11, 2002, Pages 4109-4115

  Wuchter, Christian ^a,b,c   Ruppert, Velia ^a,b,c   Schrappe, Martin ^a,b,c   Dörken, Bernd ^a,b,c   Ludwig, Wolf Dieter ^a,b,c   Karawajew, Leonid ^a,b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HELIOS Klinikum Berlin   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 7; LIPOCORTIN 5; T6 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL MATURATION; CHILD; CHILDHOOD LEUKEMIA; CORRELATION ANALYSIS; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA;

EID: 0036624894     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.4109     Document Type: Article

References (43)

1. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:735-746.
2. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-3133.
3. Ludwig WD, Harbott J, Bartram CR, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: Experience of the BFM study 86. Recent Results Cancer Res. 1993;131:269-282.
4. Niehues T, Kapaun P, Harms DO, et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999;13:614-617.
5. Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL: A Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696-1707.
6. Uckun FM, Steinherz PG, Sather H, et al. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: A Children's Cancer Group study. Blood. 1996;88:4288-4295.
7. Pui CH, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 1990;75:174-179.
8. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
9. Houghton JA. Apoptosis and drug response. Curr Opin Oncol. 1999;11:475-481.
10. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies. Blood. 1999;93:3587-3600.
11. Kaspers GJ, Veerman AJ, Van Wering ER, et al. Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia. Leukemia. 1996;10:675-681.
12. Karawajew L, Ruppert V, Wuchter C, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood. 2000;96:297-306.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
14. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898-1909.
15. Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood. 1995;86:3097-3108.
16. Béné MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
17. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-1217.
18. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
19. Kaspers GJ, Veerman AJ, Popp Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:114-121.
20. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998;92:259-266.
21. Itc C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2370-2376.
22. Kaspers GJ, Kardos G, Pieters R, et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A preliminary report. Leukemia. 1994;8:1224-1229.
23. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and Cytogenetics. Leukemia. 1999;13:1943-1953.
24. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309-345.
25. Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110:154-160.
26. Uckun FM, Yang Z, Sather H, et al. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group Study. Blood. 1997;89:3769-3777.
27. Duyn AE, Kaspers GJ, Pieters R, et al. Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. Ann Hematol. 1999;78:163-171.
28. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 2001;98:1524-1531.
29. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14:399-402.
30. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL-receptors gene expression and constitutive NF-kB activity. Leukemia. 2001;15:921-928.
31. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14:2314-2329.
32. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 1997;16:4698-4707.
33. Wissink S, van Heerde EC, Schmitz ML, et al. Distinct domains of the ReIA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem. 1997;272:22278-22284.
34. Banerjee A, Rothman P. IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling. J Immunol. 1998;161:4611-4617.
35. Chene L, Nugeyre MT, Guillemard E, Moulian N, Barre Sinoussi F, Israel N. Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: A critical role for tumor necrosis factor and interleukin-7. J Virol. 1999;73:7533-7542.
36. Chene L, Nugeyre MT, Barre Sinoussi F, Israel N. High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells. J Virol. 1999;73:2064-2073.
37. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95:19-29.
38. Ihle JN. STATs: Signal transducers and activators of transcription. Cell. 1996;84:331-334.
39. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723-2729.
40. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399-403.
41. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implications for treatment of infants. Leukemia. 1998;12:1344-1348.
42. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma. 1995;19:407-416.
43. Pieters R, Kaspers GJ, van Wering ER, et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:392-397.